Acceleron Reports Fourth Quarter and Full Year 2020 Financial Results
The Company recognized approximately $23.0 million in royalty revenue from approximately $115 million in net sales of REBLOZYL in the fourth quarter of 2020.
- The Company recognized approximately $23.0 million in royalty revenue from approximately $115 million in net sales of REBLOZYL in the fourth quarter of 2020.
- Costs and Expenses Total costs and expenses for the fourth quarter of 2020 were $83.5 million.
- Net Loss The Company's net loss for the fourth quarter of 2020 was $57.4 million.
- The Company will host a webcast and conference call to discuss its fourth quarter and full year 2020 financial results on February 25, 2021, at 5:00 p.m. EST.